Global Levosulpiride Market Size By Type (<98%, <98%), By Application (Tablet, Capsule), By Region, And Segment Forecasts, 2023 to 2032

The Global Levosulpiride Market was valued at USD 437.2 million in 2023 and is projected to reach USD 728.9 million by 2031, growing at a CAGR of 6.3% during the forecast period from 2023 to 2031. The growth is primarily driven by the increasing prevalence of gastrointestinal disorders, rising awareness regarding mental health, and the expanding use of levosulpiride in treating functional dyspepsia, irritable bowel syndrome, and schizophrenia. Pharmaceutical advancements and the surge in geriatric population prone to these conditions are further accelerating market demand.

Drivers:

1. Increasing Prevalence of Gastrointestinal Disorders:

The growing incidence of gastric motility-related issues, including dyspepsia and GERD (Gastroesophageal Reflux Disease), is a key driver for levosulpiride. Its prokinetic and antipsychotic properties make it an ideal therapeutic solution for both digestive and psychological disorders.

2. Growing Geriatric Population:

With a rising elderly demographic worldwide, particularly in Asia-Pacific and Europe, the susceptibility to gastrointestinal and neuropsychiatric conditions is increasing, fueling the demand for levosulpiride-based therapeutics.

3. Rise in Mental Health Awareness:

The use of levosulpiride in managing negative symptoms of schizophrenia and depression has become more prominent. Increased awareness and screening for mental health issues are pushing up prescriptions and market adoption.

Restraints:

1. Side Effects and Contraindications:

Levosulpiride may cause adverse effects such as hormonal imbalance, extrapyramidal symptoms, and galactorrhea, limiting its usage in sensitive populations and hampering broader adoption.

2. Regulatory Hurdles:

Stringent regulatory requirements and delayed drug approvals in various countries can act as barriers to market expansion, especially for new formulations or generics.

Opportunity:

1. Expansion in Emerging Markets:

Regions such as Latin America, Southeast Asia, and the Middle East are witnessing growing demand for gastrointestinal and neuropsychiatric treatments, offering lucrative opportunities for market penetration.

2. Combination Drug Development:

The development of combination therapies involving levosulpiride and other compounds, such as proton pump inhibitors, is gaining traction for more effective symptom control and patient compliance.

Market by System Type Insights:

Based on formulation, the Oral Tablet segment accounted for the largest share in 2023 due to its ease of administration, longer shelf life, and wide availability. However, the Injectable segment is expected to grow rapidly, driven by the need for rapid symptom control in acute cases in clinical settings.

Market by End-use Insights:

Hospitals held the dominant position in 2023 as the primary centers for prescribing and dispensing levosulpiride, especially for acute and psychiatric indications. The Retail Pharmacy segment is expected to register robust growth, supported by rising outpatient prescriptions and chronic condition management trends.

Market by Regional Insights:

Asia-Pacific led the global levosulpiride market in 2023, owing to high disease burden, generic drug penetration, and an expanding middle-class population with access to healthcare. Europe is anticipated to witness steady growth due to rising mental health diagnoses and supportive reimbursement policies. North America, while holding a smaller share, is expected to grow due to increasing off-label use and novel formulation approvals.

Competitive Scenario:

Key players in the Global Levosulpiride Market include Torrent Pharmaceuticals Ltd., Abbott Laboratories, Cadila Pharmaceuticals, Sanofi S.A., Intas Pharmaceuticals Ltd., Cipla Ltd., and Lupin Limited. These companies focus on product innovation, regional expansions, and licensing agreements to strengthen their foothold. For example:

In 2024, Torrent Pharmaceuticals launched a fixed-dose combination of levosulpiride and esomeprazole for GERD treatment in India.

Abbott Laboratories expanded its CNS drug portfolio by acquiring regional distribution rights for levosulpiride-based antipsychotic solutions in Eastern Europe in 2023.

Scope of Work – Global Levosulpiride Market

Key Market Developments:

January 2024 – Intas Pharmaceuticals received approval for a new oral disintegrating tablet form of levosulpiride aimed at elderly patients with swallowing difficulties.

March 2023 – Cipla Ltd. announced a licensing agreement with a Japanese biotech firm to co-develop a slow-release levosulpiride formulation for schizophrenia treatment.

November 2023 – Lupin Limited expanded its levosulpiride-based product offerings to Southeast Asia through a regional distribution partnership.

FAQs:

1) What is the current market size of the Global Levosulpiride Market?

The Global Levosulpiride Market was valued at USD 437.2 million in 2023.

2) What is the major growth driver of the Global Levosulpiride Market?

The increasing prevalence of gastrointestinal and mental health disorders is a primary growth driver.

3) Which is the largest region during the forecast period in the Global Levosulpiride Market?

Asia-Pacific holds the largest market share due to high disease burden and generic penetration.

4) Which segment accounted for the largest market share in Global Levosulpiride Market?

The Oral Tablet segment accounted for the largest share in 2023.

5) Who are the key market players in the Global Levosulpiride Market?

Major players include Torrent Pharmaceuticals, Abbott, Cipla, Sanofi, Intas, and Lupin.